Sanofi Kills Phase 1 STAT6 Degrader, Wiping Out Nurix's SAR448272 Milestones
NRIX sits 53% above its 52-week low of $11.67.
Summary
Sanofi discontinued the Phase 1 trial of SAR448272 and terminated the program outright, so Nurix will collect none of the future development, regulatory or commercial milestones or royalties tied to it. The release gives no dollar value or timing for the foregone payments, so the hit is to partnered-pipeline optionality rather than to near-term cash. Nurix says its runway guidance is unchanged: $1.1B in cash and securities at August 31, 2026 funds operations into the second half of 2029. That cushion is what keeps this from being a thesis-breaker — the company's own Phase 3 asset bexobrutideg and the rest of the Sanofi-licensed portfolio remain eligible for payments, though Sanofi decides whether to advance them. This lands alongside the 8-K filed the same evening and follows the October 5 news that Gilead extended a Nurix research term by two years, a reminder that partner decisions cut both ways.
At the time of this announcement, NRIX was trading at $17.88 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $11.67 to $28.23. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Wiseek News.